Cargando…

Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years

Detalles Bibliográficos
Autores principales:	Olliaro, Piero L., Kuesel, Annette C., Halleux, Christine M., Sullivan, Mark, Reeder, John C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Viewpoints
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237288/ https://www.ncbi.nlm.nih.gov/pubmed/30439940 http://dx.doi.org/10.1371/journal.pntd.0006837

Ejemplares similares

Changing FDA Approval Standards: Ethical Implications for Patient Consent
por: Darrow, Jonathan J., et al.
Publicado: (2021)

Priorities for the Priority Review Voucher
por: Ridley, David B.
Publicado: (2017)

Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development
por: Brockmann, Rouen, et al.
Publicado: (2023)

A Changing Model for Developing Health Products for Poverty-Related Infectious Diseases
por: Olliaro, Piero L., et al.
Publicado: (2015)

Osteopontin: a new role for a familiar actor
por: Johnston, Nicholas IF, et al.
Publicado: (2008)

Analysis of Neglected Tropical Disease Drug and Vaccine Development Pipelines to Predict Issuance of FDA Priority Review Vouchers over the Next Decade
por: Stefanakis, Rianna, et al.
Publicado: (2012)

More Efficient Ways of Assessing Treatments for Neglected Tropical Diseases Are Required: Innovative Study Designs, New Endpoints, and Markers of Effects
por: Olliaro, Piero, et al.
Publicado: (2012)

Knowledge Transfers and Business Performance in Creative Networks: The Case Study of the Slovak Creative Voucher Scheme
por: Baláž, Vladimír, et al.
Publicado: (2023)

The Impact of the Priority Review Voucher on Research and Development for Tropical Diseases
por: Aerts, Celine, et al.
Publicado: (2022)

Bridging global health actors and agendas: the role of national public health institutes
por: Myhre, Sonja, et al.
Publicado: (2022)

Priority-setting, the Indian way
por: Rao, Neethi V, et al.
Publicado: (2018)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Time to reconsider the role of ribavirin in Lassa fever
por: Salam, Alex Paddy, et al.
Publicado: (2021)

Treatment of Pregnant Women with Ivermectin during Mass Drug Distribution: Time to Investigate Its Safety and Potential Benefits
por: Erber, Astrid Christine, et al.
Publicado: (2021)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Priority Review Vouchers: GAO Report Provides Scant Evidence of Success
por: Meyer, Robert J.
Publicado: (2020)

Correction to: The Impact of the Priority Review Voucher on Research and Development for Tropical Diseases
por: Aerts, Celine, et al.
Publicado: (2022)

The approval of the first malaria vaccine: The beginning of the end of the malaria epidemic
por: Olufadewa, Isaac, et al.
Publicado: (2022)

Floods in Southeast Asia: A health priority
por: Torti, Jacqueline
Publicado: (2012)

Aligning values and outcomes in priority–setting for health
por: Seidman, Gabriel, et al.
Publicado: (2016)

Recognition of fungal priority pathogens: What next?
por: Rodrigues, Marcio L., et al.
Publicado: (2023)

NTD policy priorities: Science, values, and agenda setting
por: Iltis, Ana S., et al.
Publicado: (2017)

Treatment-shortening regimens for tuberculosis: updates and future priorities
por: Saluzzo, Francesca, et al.
Publicado: (2023)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Is the priority review voucher program stimulating new drug development for tropical diseases?
por: Kerr, Kirk W., et al.
Publicado: (2018)

Setting priorities for development of emerging interventions against childhood diarrhoea
por: Bhutta, Zulfiqar A., et al.
Publicado: (2013)

Dams and Disease Triggers on the Lower Mekong River
por: Ziegler, Alan D., et al.
Publicado: (2013)

FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches
por: Zushin, Peter-James H., et al.
Publicado: (2023)

Redefining global health priorities: Improving cancer care in developing settings
por: Moten, Asad, et al.
Publicado: (2014)

A neglected priority? The importance of surgery in tackling global health inequalities
por: Kennedy, Ewan D., et al.
Publicado: (2015)

Cardiovascular and cardiometabolic prevention: high-level priority in the era of COVID-19
por: Dhindsa, Devinder, et al.
Publicado: (2020)

Core Minimal Datasets to Advance Clinical Research for Priority Epidemic Diseases
por: Rojek, Amanda M, et al.
Publicado: (2020)

Research Priorities to End the Adolescent HIV Epidemic in the United States: Viewpoint
por: Fernandez, M Isabel, et al.
Publicado: (2021)

Latin America Priorities after 40 years of the beginning of the HIV pandemic
por: Sued, Omar, et al.
Publicado: (2021)

Setting priorities for development of emerging interventions against childhood pneumonia, meningitis and influenza
por: Rudan, Igor, et al.
Publicado: (2012)

Setting health research priorities using the CHNRI method: III. Involving stakeholders
por: Yoshida, Sachiyo, et al.
Publicado: (2016)

Setting health research priorities using the CHNRI method: I. Involving funders
por: Rudan, Igor, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pqi749avpckhpd18ee3ufcg1ga